NYSEHealth CareMedical - DevicesSnapshot 2026-08-31
Reading ABT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Adjusted EPS growth to about $5.48 per share in 2026: FY26 EPS guidance mid $5.53 vs target $5.48.
Abbott aims for 6.5% to 7.5% organic sales growth in 2026. Adjusted EPS is guided around $5.48 per share for 2026. The company cleared a major legal risk, reducing uncertainty. Abbott's acquisition of Exact Sciences supports growth in oncology diagnostics.
Abbott faces a lawsuit over PediaSure that could hurt sales and reputation. EPS growth may be pressured by acquisition dilution and soft guidance. Revenue growth below 6.5% would challenge management's targets.
The price is about 15% below our fair value near $112. Analysts expect roughly 14% revenue growth, which is slightly above management's 6.5% to 7.5% organic growth target. Our fair value is 6% below the Street median, reflecting some caution.
Breaks if: EPS falls below $5.12 in FY26
Breaks if: Failure to realize synergies or integration setbacks reported
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent growth. The current thesis state is intact, supported by strong recent financial performance and management's reaffirmed guidance.
The market currently prices ABT as relatively cheap compared to its peers, with a slight expectations gap. There is a low level of fragility in the stock, indicating that the current valuation is justified.
Fundamentals are likely to remain stable, driven by management's focus on organic sales growth and adjusted EPS growth. Recent results have shown strong momentum, although there is a moderate risk from potential guidance cuts or broader economic concerns.
The thesis hinges on the performance of the healthcare sector and the ability of ABT to meet its growth targets. Key factors include the outcomes of upcoming earnings reports from sector peers and management's execution on synergies from the Exact Sciences acquisition.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. FDA clearance for new products enhances the growth potential of the pipeline. Adjusted EPS growth guidance for 2026 is set between $5.45 and $5.60.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Legal rulings cause significant financial or reputational damage
Breaks if: Organic revenue growth falls below 6.5% in FY26
Over the next 1 to 3 years, ABT appears well-positioned to navigate challenges while pursuing growth. Not investment advice.
